The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Migraine is a neurological condition that typically causes painful headache attacks that occur with additional symptoms, such as sensitivity to light, sound, smell, or touch. Migraine treatment medications aim to alleviate or prevent migraine headaches.
Global Migraine Treatment Medication market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Migraine Treatment Medication market research.
Key companies engaged in the Migraine Treatment Medication industry include GSK, Pfizer, Novartis, Teva, Sun Pharma, Grünenthal, Endo Pharmaceuticals, Merck and Johnson & Johnson, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Migraine Treatment Medication were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Migraine Treatment Medication market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Migraine Treatment Medication market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- GSK
- Pfizer
- Novartis
- Teva
- Sun Pharma
- Grünenthal
- Endo Pharmaceuticals
- Merck
- Johnson & Johnson
- AbbVie
- Abbott
- Bayer
- Eli Lilly
- Kowa Pharmaceuticals America
- AstraZeneca
Segment by Type
- Triptans
- NSAIDs
- Others
Segment by Application
- Acute Migraine
- Chronic Migraine
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
- Latin America (Mexico, Brazil, Rest of Latin America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
The Migraine Treatment Medication report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Migraine Treatment Medication Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Triptans
1.2.3 NSAIDs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Migraine Treatment Medication Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Acute Migraine
1.3.3 Chronic Migraine
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Migraine Treatment Medication Market Perspective (2018-2029)
2.2 Migraine Treatment Medication Growth Trends by Region
2.2.1 Global Migraine Treatment Medication Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Migraine Treatment Medication Historic Market Size by Region (2018-2023)
2.2.3 Migraine Treatment Medication Forecasted Market Size by Region (2024-2029)
2.3 Migraine Treatment Medication Market Dynamics
2.3.1 Migraine Treatment Medication Industry Trends
2.3.2 Migraine Treatment Medication Market Drivers
2.3.3 Migraine Treatment Medication Market Challenges
2.3.4 Migraine Treatment Medication Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Migraine Treatment Medication Players by Revenue
3.1.1 Global Top Migraine Treatment Medication Players by Revenue (2018-2023)
3.1.2 Global Migraine Treatment Medication Revenue Market Share by Players (2018-2023)
3.2 Global Migraine Treatment Medication Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Migraine Treatment Medication Revenue
3.4 Global Migraine Treatment Medication Market Concentration Ratio
3.4.1 Global Migraine Treatment Medication Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Migraine Treatment Medication Revenue in 2022
3.5 Migraine Treatment Medication Key Players Head office and Area Served
3.6 Key Players Migraine Treatment Medication Product Solution and Service
3.7 Date of Enter into Migraine Treatment Medication Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Migraine Treatment Medication Breakdown Data by Type
4.1 Global Migraine Treatment Medication Historic Market Size by Type (2018-2023)
4.2 Global Migraine Treatment Medication Forecasted Market Size by Type (2024-2029)
5 Migraine Treatment Medication Breakdown Data by Application
5.1 Global Migraine Treatment Medication Historic Market Size by Application (2018-2023)
5.2 Global Migraine Treatment Medication Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Migraine Treatment Medication Market Size (2018-2029)
6.2 North America Migraine Treatment Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Migraine Treatment Medication Market Size by Country (2018-2023)
6.4 North America Migraine Treatment Medication Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Migraine Treatment Medication Market Size (2018-2029)
7.2 Europe Migraine Treatment Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Migraine Treatment Medication Market Size by Country (2018-2023)
7.4 Europe Migraine Treatment Medication Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Migraine Treatment Medication Market Size (2018-2029)
8.2 Asia-Pacific Migraine Treatment Medication Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Migraine Treatment Medication Market Size by Region (2018-2023)
8.4 Asia-Pacific Migraine Treatment Medication Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Migraine Treatment Medication Market Size (2018-2029)
9.2 Latin America Migraine Treatment Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Migraine Treatment Medication Market Size by Country (2018-2023)
9.4 Latin America Migraine Treatment Medication Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Migraine Treatment Medication Market Size (2018-2029)
10.2 Middle East & Africa Migraine Treatment Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Migraine Treatment Medication Market Size by Country (2018-2023)
10.4 Middle East & Africa Migraine Treatment Medication Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Migraine Treatment Medication Introduction
11.1.4 GSK Revenue in Migraine Treatment Medication Business (2018-2023)
11.1.5 GSK Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Migraine Treatment Medication Introduction
11.2.4 Pfizer Revenue in Migraine Treatment Medication Business (2018-2023)
11.2.5 Pfizer Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Migraine Treatment Medication Introduction
11.3.4 Novartis Revenue in Migraine Treatment Medication Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Teva
11.4.1 Teva Company Detail
11.4.2 Teva Business Overview
11.4.3 Teva Migraine Treatment Medication Introduction
11.4.4 Teva Revenue in Migraine Treatment Medication Business (2018-2023)
11.4.5 Teva Recent Development
11.5 Sun Pharma
11.5.1 Sun Pharma Company Detail
11.5.2 Sun Pharma Business Overview
11.5.3 Sun Pharma Migraine Treatment Medication Introduction
11.5.4 Sun Pharma Revenue in Migraine Treatment Medication Business (2018-2023)
11.5.5 Sun Pharma Recent Development
11.6 Grünenthal
11.6.1 Grünenthal Company Detail
11.6.2 Grünenthal Business Overview
11.6.3 Grünenthal Migraine Treatment Medication Introduction
11.6.4 Grünenthal Revenue in Migraine Treatment Medication Business (2018-2023)
11.6.5 Grünenthal Recent Development
11.7 Endo Pharmaceuticals
11.7.1 Endo Pharmaceuticals Company Detail
11.7.2 Endo Pharmaceuticals Business Overview
11.7.3 Endo Pharmaceuticals Migraine Treatment Medication Introduction
11.7.4 Endo Pharmaceuticals Revenue in Migraine Treatment Medication Business (2018-2023)
11.7.5 Endo Pharmaceuticals Recent Development
11.8 Merck
11.8.1 Merck Company Detail
11.8.2 Merck Business Overview
11.8.3 Merck Migraine Treatment Medication Introduction
11.8.4 Merck Revenue in Migraine Treatment Medication Business (2018-2023)
11.8.5 Merck Recent Development
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Detail
11.9.2 Johnson & Johnson Business Overview
11.9.3 Johnson & Johnson Migraine Treatment Medication Introduction
11.9.4 Johnson & Johnson Revenue in Migraine Treatment Medication Business (2018-2023)
11.9.5 Johnson & Johnson Recent Development
11.10 AbbVie
11.10.1 AbbVie Company Detail
11.10.2 AbbVie Business Overview
11.10.3 AbbVie Migraine Treatment Medication Introduction
11.10.4 AbbVie Revenue in Migraine Treatment Medication Business (2018-2023)
11.10.5 AbbVie Recent Development
11.11 Abbott
11.11.1 Abbott Company Detail
11.11.2 Abbott Business Overview
11.11.3 Abbott Migraine Treatment Medication Introduction
11.11.4 Abbott Revenue in Migraine Treatment Medication Business (2018-2023)
11.11.5 Abbott Recent Development
11.12 Bayer
11.12.1 Bayer Company Detail
11.12.2 Bayer Business Overview
11.12.3 Bayer Migraine Treatment Medication Introduction
11.12.4 Bayer Revenue in Migraine Treatment Medication Business (2018-2023)
11.12.5 Bayer Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Detail
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Migraine Treatment Medication Introduction
11.13.4 Eli Lilly Revenue in Migraine Treatment Medication Business (2018-2023)
11.13.5 Eli Lilly Recent Development
11.14 Kowa Pharmaceuticals America
11.14.1 Kowa Pharmaceuticals America Company Detail
11.14.2 Kowa Pharmaceuticals America Business Overview
11.14.3 Kowa Pharmaceuticals America Migraine Treatment Medication Introduction
11.14.4 Kowa Pharmaceuticals America Revenue in Migraine Treatment Medication Business (2018-2023)
11.14.5 Kowa Pharmaceuticals America Recent Development
11.15 AstraZeneca
11.15.1 AstraZeneca Company Detail
11.15.2 AstraZeneca Business Overview
11.15.3 AstraZeneca Migraine Treatment Medication Introduction
11.15.4 AstraZeneca Revenue in Migraine Treatment Medication Business (2018-2023)
11.15.5 AstraZeneca Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
